144 related articles for article (PubMed ID: 34105479)
1. [Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].
Zhang CX; Wang HT; Zhang GJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Jun; 29(3):827-831. PubMed ID: 34105479
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
3. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
4. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
5. [Long-Term Retrospective Analysis of Prognostic Factors in Patients with Newly Diagnosed Multiple Myeloma without Hematopoietic Stem Cell Transplantation].
Wang H; Zhou X; Zhu JW; Ye JN; Li JY; Sun C
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1530-1539. PubMed ID: 31607308
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
7. [Prognostic significance of CD56 and CD117 expression in patients with newly diagnosed multiple myeloma treated with bortezomib-based first-line therapy].
Shi J; Sun K; Zhu ZM; Lei PC; Liu ZW; Chen YQ; Guo JM; Zang YZ; Yang J; Zhang Y
Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):693-696. PubMed ID: 31495142
[No Abstract] [Full Text] [Related]
8. [Clinical significance of abnormal protein bands in multiple myeloma treated with bortezomib-based induction regimen and autologous stem cell transplantation].
Wang HH; Li J; Liu JR; Zheng D; Gu JL; Yan MS; Zou WY; Xu DR
Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):327-31. PubMed ID: 23668206
[TBL] [Abstract][Full Text] [Related]
9. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
10. Association of CD117 and HLA-DR expression with shorter overall survival and/or progression-free survival in patients with multiple myeloma treated with bortezomib and thalidomide combination treatment without transplantation.
Wang H; Zhou X; Zhu JW; Ye JN; Guo HF; Sun C
Oncol Lett; 2018 Nov; 16(5):5655-5666. PubMed ID: 30344721
[TBL] [Abstract][Full Text] [Related]
11. [Predictive Value of Pre-treatment Serum Uric Acid Level for Prognosis in Newly Diagnosed Patients with Multiple Myeloma].
Xu SQ; Zhao P; Wang ZH; Deng H; Zhang L; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1216-1223. PubMed ID: 34362505
[TBL] [Abstract][Full Text] [Related]
12. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study.
Li L; Li X; Shang A; Zhao Y; Jin L; Zhao M; Shen W
Medicine (Baltimore); 2022 Oct; 101(40):e30988. PubMed ID: 36221376
[TBL] [Abstract][Full Text] [Related]
14. [Influence of Combination with 1q21 Amplification or-No in Patients with Newly Diagnosed MM on the Clinical Effecacy of Bortezomib-based induction chemotherapy and Long-Term Prognosis of Patients].
Gu WW; Wang JS; Mu K; Ren G
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Aug; 28(4):1251-1255. PubMed ID: 32798407
[TBL] [Abstract][Full Text] [Related]
15. CD56 expression in multiple myeloma: Correlation with poor prognostic markers but no effect on outcome.
Koumpis E; Tassi I; Malea T; Papathanasiou K; Papakonstantinou I; Serpanou A; Tsolas E; Kapsali E; Vassilakopoulos TP; Papoudou-Bai A; Hatzimichael E
Pathol Res Pract; 2021 Sep; 225():153567. PubMed ID: 34352440
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis.
Zhang L; Huang Y; Lin Y; Zhang A; Zou R; Xu H; Wang S
Hematology; 2022 Dec; 27(1):122-131. PubMed ID: 35068378
[TBL] [Abstract][Full Text] [Related]
17. CD27 antigen negative expression indicates poor prognosis in newly diagnosed multiple myeloma.
Chu B; Bao L; Wang Y; Lu M; Shi L; Gao S; Fang L; Xiang Q; Liu X
Clin Immunol; 2020 Apr; 213():108363. PubMed ID: 32120013
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 1q21 amplification on bortezomib therapeutic response and prognosis of newly diagnosed multiple myeloma patients].
Liu XL; Yang PY; Yu XY; Chen JC; Liu XL; Bai J; Liu YM; He H; Sun JN; Fan HQ; Zhang C; Zhang Y; Su KJ; Liu CS; Tan YH; Gao SJ; Li W; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):408-413. PubMed ID: 29779352
[No Abstract] [Full Text] [Related]
19. LDH is an adverse prognostic factor independent of ISS in transplant-eligible myeloma patients receiving bortezomib-based induction regimens.
Chim CS; Sim J; Tam S; Tse E; Lie AK; Kwong YL
Eur J Haematol; 2015 Apr; 94(4):330-5. PubMed ID: 25135740
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of bortezomib-based therapy in Taiwanese patients with multiple myeloma: A nationwide population-based study and a single-institute analysis.
Liu WN; Chang CF; Chung CH; Chien WC; Huang TC; Wu YY; Ho CL; Chen JH
PLoS One; 2019; 14(9):e0222522. PubMed ID: 31527921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
